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Myeloproliferative neoplasmMyeloproliferative neoplasms (MPNs) are clinically characterizedby the chronic overproduction of differentiated
peripheral blood cells and the gradual expansion of malignant intramedullary/extramedullary hematopoiesis. In
MPNsmutations in JAK2 MPL or CALR are detectedmutually exclusive inmore than 90% of cases [1,2]. Mutations
in them lead to the abnormal activation of JAK/STAT signaling and the autonomous growth of differentiated
cells therefore they are considered as “driver” gene mutations. In addition to the above driver gene mutations
mutations in epigenetic regulators such as TET2 DNMT3A ASXL1 EZH2 or IDH1/2 are detected in about 5%–30%
of cases respectively [3]. Mutations in TET2 DNMT3A EZH2 or IDH1/2 commonly confer the increased self-
renewal capacity on normal hematopoietic stem cells (HSCs) but they do not lead to the autonomous growth
of differentiated cells and only exhibit subtle clinical phenotypes [4,6–8,5]. It was unclear how mutations in
such epigenetic regulators inﬂuenced abnormal HSCs with driver gene mutations how they inﬂuenced the
disease phenotype or whether a single driver gene mutation was sufﬁcient for the initiation of human MPNs.
Therefore we focused on JAK2V617F and loss of TET2—the former as a representative of driver gene mutations
and the latter as a representative of mutations in epigenetic regulators—and examined the inﬂuence of single
or double mutations on HSCs (Lineage−Sca-1+c-Kit+ cells (LSKs)) by functional analyses and microarray
whole-genome expression analyses [9]. Gene expression proﬁling showed that the HSC ﬁngerprint genes [10]
was statistically equally enriched in TET2-knockdown-LSKs but negatively enriched in JAK2V617F–LSKs
compared to that in wild-type-LSKs. Double-mutant-LSKs showed the same tendency as JAK2V617F–LSKs
in terms of their HSC ﬁngerprint genes but the expression of individual genes differed between the two groups.
Among 245 HSC ﬁngerprint genes 100 were more highly expressed in double-mutant-LSKs than in JAK2V617F–
LSKs. These altered gene expressionsmight partly explain themechanisms of initiation and progression ofMPNs
which was observed in the functional analyses [9]. Here we describe gene expression proﬁles deposited at the
Gene Expression Omnibus (GEO) under the accession number GSE62302 including experimental methods and
quality control analyses.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).logy and Hematology, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan. Tel.: +81
himoda).
. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Speciﬁcations
Organism/cell line/tissue Musmusculus, C57BL/6, bone marrow Lineage−Sca-1+c-Kit+
cells (LSKs)
Sex Not applicable: each fetus was genotyped for JAK2 and
TET2, but was not determined by gender; for each
genotype, fetal liver cells (FLs) were collected from
multiple fetuses and mixed altogether, and were
transplanted into lethally irradiated recipients; therefore
the gender of recipients' LSKs derived from transplanted
FLs was not to be determined.
Sequencer or array type Agilent-028005 SurePrint G3 Mouse GE 8x60K Microarray
Data format Raw and analyzed
Experimental factors Genotype: Wild type vs. TET2 knock-down (TET2KD),
JAK2V617F, or TET2KD and JAK2V617F (double-mutant);
JAK2V617F vs. double-mutant.
Experimental features Microarray gene expression proﬁling to identify genes
that are regulated by loss of TET2 and/or JAK2V617F.
Consent Animal studies were performed in accordance with the
local University of Miyazaki Ethics Committee.
Sample source location Not applicable
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Experimental design, materials and methods
Mouse usage
JAK2V617F transgenic mice [11] and TET2 heterozygous knockdown
(TET2trap/+) mice [5] generated by gene trapping were previously
reported. They were backcrossed at least 8 times onto C57BL/6 mice
(B6-CD45.2). The TET2trap/trap mice frequently died during the neonatal
period on the B6-CD45.2 background; therefore, we transplanted
their fetal liver (FL) cells (FLs) to generate mouse models of myelopro-
liferative neoplasms (MPNs). For the transplantation, we crossed
male JAK2V617F–TET2trap/+ mice with female TET2trap/+ mice, and
obtained the following 4 experimental groups of E14.5 fetuses:
JAK2WT–TET2WT (wild-type (WT)), JAK2WT–TET2trap/trap (TET2-
knockdown (TET2KD)), JAK2V617F–TET2WT (JAK2V617F), and
JAK2V617F–TET2trap/trap (double-mutant) (Table 1). B6 mice congenic
for the CD45.1 locus (B6-CD45.1) were purchased as recipients (Sankyo
Laboratory Service, Tsukuba, Japan). Animal studies were performed
in accordance with the local University of Miyazaki Ethics Committee.
Generation of mouse models of MPNs
We non-competitively transplanted 1 × 106 of 4 experimental
groups of E14.5 FLs (WT, TET2KD, JAK2V617F, double-mutant) into
lethally irradiated B6-CD45.1 mice [9]. Compared with the recipients
transplanted with WT cells, the recipients of TET2KD cells showed
normal blood cell count, no splenomegaly, comparable overall survival
duration, and minimal extramedullary hematopoiesis of the lung andTable 1
Four experimental groups deﬁned by the JAK2-and-TET2 mutation status of the
experimental tissues or cells.
Annotation JAK2 status TET2 status
WT JAK2WT TET2WT
TET2KD JAK2WT TET2trap/trap
JAK2V617F JAK2V617F TET2WT
Double-mutant JAK2V617F TET2trap/trapliver, indicating that TET2KD cells developed only a subtle clinical
phenotype asMPNs. Recipients of JAK2V617F cells showed leukocytosis,
anemia, thrombocytosis, splenomegaly, shorter survival duration,
moderate extramedullary hematopoiesis, and ﬁbrosis in bone marrow
(BM) and spleen, indicating that JAK2V617F cells induced clinically
primary myeloﬁbrosis (PMF)-like MPNs. Double-mutant cells showed
not only the phenotype of JAK2V617F cell recipients, but also prolonged
leukocytosis, splenomegaly, and severe extramedullary hematopoiesis,
with modestly shorter overall survival. These results indicated that
the combination of loss of TET2 and JAK2V617F worsened the disease
compared to single-mutant JAK2V617F-induced MPNs.
RNA and cDNA preparation for microarray gene expression analyses
To identify genes regulated by loss of TET2 and/or JAK2V617F, we
performed microarray gene expression analyses. For the cell prepara-
tion, we sacriﬁced the 4 experimental groups of recipients at 10–
16 weeks post-transplantation, and sorted Lineage−Sca-1+c-Kit+ cells
(LSKs) from the BM of the recipients by FACSAriaII (BD Biosciences,
San Jose, USA). WT-LSKs (n = 1), TET2KD–LSKs (n = 1), JAK2V617F–
LSKs (n = 1), and double-mutant-LSKs (n = 1) were each pooled
from 5 mice (Table 1), and preserved in TRIzol reagent. RNA samples
were isolated from the each pooled 2–6 × 104 BM-LSKs. cDNA samples
were prepared from 2–5 ng RNA samples using the Ovation Pico
WTA System V2 (NuGEN, San Carlos, CA), according to the
manufacturer's instructions. The NuGENOvation ampliﬁcationmethod-
ology uses an isothermal linear ampliﬁcation using DNA/RNA chimeric
primers.
cDNA labeling and hybridization
Two μg of puriﬁed and ampliﬁed cDNA was used as input into the
Agilent Genomic DNA Enzymatic Labeling Kit (Agilent Technologies,
Palo Alto, CA), according to the manufacturer's instructions. The Cy3-
labeled cDNA was quantiﬁed and dye incorporation determined
by Nanodrop ND-1000 Spectrophotometer (Thermo Fisher Scientiﬁc,
Waltham, MA). For each hybridization, 1.65 μg of Cy3-labeled cDNA
was hybridized at 65 °C for 17 h to an Agilent Mouse GE 8x60K
Microarray (Agilent, Design ID: 028005). After washing, microarrays
were scanned using an Agilent DNA microarray scanner (Agilent).
Microarray study design
Using the 4 experimental groups of prepared cDNA samples (each,
n = 1), microarray gene expression analyses were performed. Each
gene expression proﬁle of TET2KD–LSKs, JAK2V617F–LSKs and double-
mutant-LSKs was compared to that of WT-LSKs; and a gene expression
proﬁle of double-mutant-LSKs was compared to that of JAK2V617F–
LSKs.
RNA and cDNA quality control analyses
RNA and cDNA qualities were assessed by Nanodrop ND-1000
Spectrophotometer (Thermo Fisher Scientiﬁc) and by the 2100
Bioanalyser (Agilent). All isolated RNA samples showed appropriate
A260/A280 ratios ranging between 1.56 and 1.72, but small peaks for
18 s and 28 s ribosomal RNA subunits and low RNA integrity numbers
(RIN) ranging between 2.7 and 5.4 in their electropherograms, probably
because of their small amounts or degradation; suggesting their insufﬁ-
cient qualities for the regularmicroarray protocol without ampliﬁcation
(Fig. 1 left column). However, according to the manufacturer's instruc-
tions, the NuGEN Ovation Pico WTA System V2 enables RNA samples
with RIN still around 2.0 to amplify successfully and reproducibly;
thereforeweperformed followingRNAampliﬁcation and cDNA synthesis.
All ampliﬁed cDNA samples showed A260/A280 ratios ranging between
1.92 and 1.96, A260/A230 ratio between 2.30 and 2.36, and typical plots
Ladder
WT
TET2KD
JAK2V617F
Double-
mutant
RNA Amplified cDNA
RIN = 2.7
RIN = 4.0
RIN = 2.5
RIN = 5.4
Fig. 1. Quality control assays of RNA samples (left column) and ampliﬁed cDNA samples (right column). Bioanalyser outputs were shown for each sample. FU, ﬂuorescence units; nt,
nucleotide. RNA integrity numbers (RIN) were displayed beside each RNA plot. All ampliﬁed cDNA samples showed typical plots between 200 and 2000 kb, indicating their sufﬁcient
qualities for microarray analysis.
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microarray protocol with ampliﬁcation (Fig. 1 right column). Finally,
all Cy3-labeled cDNA samples showed A260/A280 ratios ranging
between 1.79 and 1.84, and dye incorporation rates ranging between
32.1 and 35.1.
Microarray quality control analyses
In each 4 experimental group of hybridization, the grid placements
were adequate (Fig. 2A). Obvious biases in the distributions of outlier
probes were not seen, and the frequencies of non-uniform features
were sufﬁciently low (b1%) (Fig. 2B).
Data normalization
There are total of 55,681 probes on Agilent Mouse GE 8x60K
Microarray (Design ID: 028005) without control probes, and intensityvalues of each scanned feature were quantiﬁed using Agilent Feature
Extraction software version 10.7.3.1, which performs background
subtractions. Normalization was performed using Agilent GeneSpring
GX version 12.6.1. (per chip: normalization to 75 percentile shift).
Data analysis (cluster analysis)
Dendrogram was constructed from unsupervised hierarchical
clustering of data sets from 4 experimental groups of BM-LSKs using
Pearson correlation. There were close similarities in the whole-genome
expression proﬁles between JAK2V617F–LSKs and double-mutant-LSKs
(Fig. 3).
Data analysis (gene set enrichment analysis (GSEA))
Gene set enrichment analysis (GSEA) [12] was performed across the
complete list of genes ranked by signal-to-noise ratio according to their
A B
Fig. 2. Quality control assays of hybridizations. (A) Adequate grid placements in each 4 experimental groups of hybridizations. (B) Absence of obvious biases in the distributions of outlier
probes and sufﬁciently low frequencies (b1%) of non-uniform features in each 4 experimental groups of hybridizations.
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assigned to each gene set and the statistical signiﬁcance of its enrich-
ment was measured by FDR q-value. Consistent with the ﬁnding from
cluster analysis, GSEA showed positive enrichment of the STAT5A target
genes [13] and pre-erythroid colony-forming unit signature genes [14]Fig. 3. Clustering analysis of data sets from 4 experimental groups of BM-LSKs. Dendro-
gram constructed from unsupervised hierarchical clustering using Pearson correlation.
There were close similarities in the whole-genome expression proﬁles between
JAK2V617F–LSKs and double-mutant-LSKs.in both JAK2V617F–LSKs and double-mutant LSKs, but not in TET2KD–
LSKs; suggesting that JAK2V617F expression induced a progenitor
phenotype in LSKs (Fig. 4A, B). Although there was no signiﬁcant
enrichment of the HSC ﬁngerprint genes [10] in TET2KD–LSKs, it was
negatively enriched in JAK2V617F–LSKs. Double-mutant-LSKs showed
the same tendency as JAK2V617F–LSKs in terms of their HSC ﬁngerprint
genes, but the expression of individual genes differed between the
two groups (Fig. 4C, D). Among 245 HSC ﬁngerprint genes, 100 (41%)
genes were highly expressed in double-mutant LSKs, compared to in
JAK2V617F–LSKs; and 37 (15%), 16 (6.5%), 6 (2.4%) and 2 (0.8%) genes
showed more than 1.0 log2 fold change (log2FC) (2 FC), 2.0 log2FC
(4 FC), 3.0 log2FC (8 FC) and 5.0 log2FC (32 FC), respectively (Table 2,
Fig. 5).Discussion
We present here a unique data set of mouse models of MPNs. This
dataset is measured by Agilent platform and composed of gene expres-
sion proﬁles of normal and mutant LSKs (WT, JAK2V617F, TET2KD,
double-mutant) (Table 1). JAK2V617F-induced HSC impairments were
identiﬁed in several mouse models of MPNs including ours [9,15,16].
In our model, though single-mutant JAK2V617F-cells could initiate
and promote MPNs during a short-term, they showed reduced self-
renewal capacity in vitro and reduced long-term oncogenic capacity
in vivo [9]. However, the double-mutant cells showed increased self-
AB
C
D
Fig. 4. Gene set enrichment analysis (GSEA) between the expression proﬁles of different LSKs (WT vs. TET2KD, JAK2V617F, or double-mutant; JAK2V617F vs. double-mutant). (A) Positive
enrichment of the STAT5A target genes both in JAK2V617F–LSKs and in double-mutant-LSKs. (B) Positive enrichment of the pre-erythroid colony-forming unit signature genes both in
JAK2V617F–LSKs and in double-mutant-LSKs. (C) Equivalent enrichment of the HSC ﬁngerprint genes in TET2KD–LSKs, and negative enrichment both in JAK2V617F–LSKs and in dou-
ble-mutant-LSKs. (D) Equivalent enrichment of the HSC ﬁngerprint genes between double-mutant-LSKs and JAK2V617F–LSKs. The normalized enrichment score (NES) from the overall
gene expression proﬁles of LSKs and the false discovery rate q-value are indicated.
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term [9], indicating that JAK2V617F-induced HSC impairments were
restored by combined loss of TET2. Also in human, those impairments
were identiﬁed in JAK2V617F–HSCs [17], and combined loss of TET2
seemed to restore the JAK2V617F-induced HSC impairments and
expand the HSC compartment by altering transcriptional programs
[17,18]. Therefore, we tried to uncover the restoration mechanisms by
using a gene-proﬁling approach in mouse models. Here, we showed
that many HSC ﬁngerprint genes were down-regulated in JAK2V617F–
LSKs, but the expressions of signiﬁcant number of them were restored
in double-mutant-LSKs (Table 2, Fig. 5), though we could not see
statistically signiﬁcant restoration of the proﬁle (Fig. 4D). These
expressional changes might partly explain themechanisms of initiation
and progression of MPNs. In spite of our and other studies [9,18,19], the
precise mechanisms by which loss of TET2 restores the JAK2V617F-
induced HSC impairments still remain poorly known, further wet and
dry investigations are necessary to uncover them more precisely.Conﬂict of interest
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Table 2
HSC ﬁngerprint genes expressed more highly in double mutant-LSKs than in JAK2V617F–LSKs.
For each HSC ﬁngerprint gene, Agilent probe ID, RefSeq ID, normalized expression values (log2) in each mutant LSKs and the value of the log2 fold change (log2FC) (Double mutant vs.
JAK2V617F) are shown. HSC ﬁngerprint genes are arranged in descending order of the value of the log2FC.
Probe ID RefSeq ID Gene symbol WT TET2KD JAK2 V617F Double-mutant log2FC (double mutant vs. JAK2V617F)
A_55_P2174935 NM_001081235 MN1 0.230 −0.936 −5.367 −0.130 5.237
A_51_P469480 NM_009535 YES1 −4.917 −4.721 −4.618 0.502 5.120
A_55_P2078710 NM_029413 MORC4 2.775 0.403 −4.103 −0.382 3.721
A_52_P17098 NM_001161620 MPP7 −2.307 −1.290 −2.043 1.666 3.709
A_51_P384148 NM_013649 RYK −5.134 −4.928 −5.348 −1.843 3.505
A_55_P2121985 NM_013829 PLCB4 −0.339 −0.537 −1.038 2.245 3.283
A_65_P16750 NM_001163609 PSMA8 −4.958 −4.351 −4.187 −1.193 2.994
A_51_P501803 NM_010451 HOXA2 −3.562 −2.678 −5.015 −2.069 2.946
A_51_P258409 NM_010423 HEY1 −4.939 −1.361 −4.175 −1.249 2.926
A_52_P121342 NM_020252 NRXN1 0.839 1.021 −2.792 0.010 2.802
A_55_P2129271 NM_001285498 TEAD2 −3.023 −1.465 −3.308 −0.683 2.625
A_55_P1955457 NM_010345 GRB10 −1.329 −1.564 −3.263 −0.660 2.603
A_51_P293781 NM_016863 FKBP1B −4.324 −1.063 −3.222 −0.629 2.593
A_55_P2066463 NM_010135 ENAH −5.220 −5.021 −4.031 −1.655 2.376
A_52_P162486 NM_007542 BGN 0.864 1.299 −5.224 −2.941 2.283
A_55_P1966644 NM_013838 TRPC6 0.286 −1.267 −3.580 −1.300 2.280
A_51_P462102 NM_133911 GPR125 −4.796 −2.431 −2.045 −0.073 1.972
A_66_P136228 NM_030690 RAI14 −1.642 1.334 −5.468 −3.539 1.929
A_66_P134991 NM_028360 TTC19 −3.783 0.111 −1.617 0.297 1.914
A_55_P1981155 NM_153537 PHLDB1 −3.791 −2.611 −5.050 −3.227 1.822
A_55_P2262136 NM_013690 TEK −1.750 −2.354 −5.453 −3.726 1.727
A_55_P2154659 NM_023651 PEX13 −4.951 −4.765 −1.839 −0.187 1.652
A_51_P258493 NM_011067 PER3 −5.172 −2.979 −4.253 −2.680 1.573
A_66_P114381 NM_001005341 YPEL2 0.865 2.139 −2.649 −1.103 1.547
A_55_P2163319 NM_008817 PEG3 −5.166 −4.958 −5.380 −3.871 1.510
A_55_P2036026 NM_028783 ROBO4 0.744 0.297 −1.038 0.469 1.506
A_55_P2137887 NM_010820 MPDZ −5.192 −5.020 −5.454 −3.969 1.485
A_55_P2000758 NM_019832 GKAP1 0.273 0.416 −1.831 −0.398 1.433
A_51_P350453 NM_013743 PDK4 −3.333 −4.200 −5.482 −4.071 1.410
A_51_P463003 NM_021367 TSLP −2.800 −4.719 −3.351 −2.000 1.351
A_55_P1968362 NM_011599 TLE1 0.466 1.850 −0.451 0.865 1.316
A_55_P2038056 NM_080285 CTTNBP2 −4.706 −4.534 −5.502 −4.272 1.230
A_51_P361220 NM_008055 FZD4 −2.366 −1.957 −4.903 −3.674 1.229
A_51_P249930 NM_146236 TCEAL1 −5.003 −3.211 −3.418 −2.247 1.171
A_52_P20048 NM_011544 TCF12 0.393 −1.130 −1.777 −0.661 1.116
A_55_P2092859 NM_013471 ANXA4 2.783 1.534 −0.644 0.459 1.103
A_55_P2109559 NM_001013616 TRIM6 −2.055 −3.687 −3.141 −2.101 1.041
Fig. 5. Venn diagram illustrating the numbers and frequencies of highly expressed HSC
ﬁngerprint genes in double-mutant-LSKs than in JAK2V617F–LSKs. Within the 245 HSC
ﬁngerprint genes, 100 (41%), 37 (15%), 16 (6.5%), 6 (2.4%) and 2 (0.8%) genes were highly
expressedmore than0 log2FC (1 FC), 1.0 log2FC (2 FC), 2.0 log2FC (4 FC), 3.0 log2FC (8 FC)
and 5.0 log2FC (32 FC), respectively.
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